Olopatadine
Chemical compound
Clinical data | |
---|---|
Trade names | Patanol, Opatanol, Allelock, others |
AHFS / Drugs.com | Monograph |
MedlinePlus | a602025 |
License data |
|
Pregnancy
category |
|
Routes of
administration |
Eye drops , nasal spray |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 3 hours |
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA ) | |
Chemical and physical data | |
Formula | C 21 H 23 N O 3 |
Molar mass | 337.419 g·mol −1 |
3D model ( JSmol ) | |
|
|
|
|
N Y (what is this?) (verify) |
Olopatadine , sold under the brand name Opatanol among others, is a medication used to decrease the symptoms of allergic conjunctivitis and allergic rhinitis (hay fever). [2] It is used as eye drops or as a nasal spray . [2] The eye drops generally result in an improvement within half an hour. [2]
Common side effects include headache, sore throat, eye discomfort, change in taste. [3] [2] More significant side effects may include sleepiness. [2] It is unclear if use during pregnancy or breastfeeding is safe. [4] It is an antihistamine and mast cell stabilizer . [5] [2]
Olopatadine was patented in 1986 and came into medical use in 1997. [6] It is available as a generic medication . [2] In 2020, it was the 268th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [7] [8]
Side effects
Some known side effects include headache (7% of occurrence), eye burning and/or stinging (5%), blurred vision, dry eyes, foreign body sensation, hyperemia , keratitis , eyelid edema , pruritus , asthenia , sore throat ( pharyngitis ), rhinitis , sinusitis , taste perversion, and vomiting.
Chemistry
Synthesis
Pharmacology
Pharmacodynamics
Olopatadine acts as a selective antagonist of the histamine H 1 receptor , thus stabilizing mast cells and inhibiting histamine release.
History
Olopatadine was patented in 1986 by Kyowa Hakko Kogyo and came into medical use in 1997. [6]
In the United States, Pataday Twice Daily Relief was first approved by the FDA in 1996, under the name Patanol as a prescription drug and was indicated for the treatment of the signs and symptoms of allergic conjunctivitis (referring to ocular redness and itching due to allergies). [1] Pataday – now Pataday Once Daily Relief – was first approved by the FDA in 2004, as a prescription drug and was indicated for the treatment of ocular itching associated with allergic conjunctivitis. [1] These drugs are mast cell stabilizers, which work by preventing the release of histamine and therefore prevent or control allergic disorders. [1]
In February 2020, Pataday Twice Daily Relief and Pataday Once Daily Relief were switched to be over-the-counter drugs in the United States when the FDA granted the approvals of the nonprescription products to Alcon . [1]
Society and culture
Brand names
Brand names include Pazeo, Pataday, Patanol S, Patanol, Opatanol, Olopat, Patanase. [10] It is also available as an oral tablet in Japan under the tradename Allelock, manufactured by Kyowa Hakko Kogyo. [11]
References
- 1 2 3 4 5 "FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process" . U.S. Food and Drug Administration (FDA) . 14 February 2020. Archived from the original on 15 February 2020 . Retrieved 14 February 2020 . This article incorporates text from this source, which is in the public domain .
- 1 2 3 4 5 6 7 "Olopatadine Hydrochloride Monograph for Professionals" . Drugs.com . American Society of Health-System Pharmacists . Retrieved 26 March 2019 .
- ↑ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1126. ISBN 9780857113382 .
- ↑ "Olopatadine ophthalmic Use During Pregnancy" . Drugs.com . Retrieved 26 March 2019 .
- ↑ Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A (June 2015). "Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis" (PDF) . The Cochrane Database of Systematic Reviews . 6 (6): CD009566. doi : 10.1002/14651858.CD009566.pub2 . hdl : 2164/6048 . PMID 26028608 .
- 1 2 Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery . John Wiley & Sons. p. 549. ISBN 9783527607495 .
- ↑ "The Top 300 of 2020" . ClinCalc . Retrieved 7 October 2022 .
- ↑ "Olopatadine - Drug Usage Statistics" . ClinCalc . Retrieved 7 October 2022 .
- ↑ Ueno K, Kubo S, Tagawa H, Yoshioka T, Tsukada W (July 1976). "6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity". Journal of Medicinal Chemistry . 19 (7): 941–6. doi : 10.1021/jm00229a017 . PMID 940112 .
- ↑ Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
- ↑ Kyowa Hakko Kogyo Co., Ltd. (2007). "Allelock Tablets 2.5 & Allelock Tablets 5 (English)" (PDF) . Archived from the original (PDF) on 22 July 2011 . Retrieved 10 August 2008 .
External links
- "Olopatadine" . Drug Information Portal . U.S. National Library of Medicine.
- "Olopatadine hydrochloride" . Drug Information Portal . U.S. National Library of Medicine.
- "Olopatadine Nasal Spray" . MedlinePlus .
Decongestants
and other nasal preparations (
R01
)
|
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Topical |
|
||||||||||
Systemic use:
Sympathomimetics |
|||||||||||
|
H 1 |
|
||||
---|---|---|---|---|---|
H 2 |
|
||||
H 3 |
|
||||
H 4 |
|
||||
Classes | |
---|---|
Antidepressants
( Tricyclic antidepressants (TCAs) ) |
|
Antihistamines |
|
Antipsychotics |
|
Anticonvulsants | |
Anticholinergics | |
Others |
|